eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
eXoZymes, Inc.NASDAQ: EXOZ
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin dips below year-ago levels
Q1 FY2026 selling, general & admin of $1.19M fell 13.4% year over year, behind the +24.9% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 24.7% from the prior quarter. Over 3 fiscal years it compounded at +91.9% a year.
Context
- Selling, general & admin increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -13.4% toward the trailing-twelve-month pace of +24.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 5.91M USD
- Year-over-year change
- +55.8%
- 4-year CAGR
- +66.0%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.91M | +55.8% |
| FY2024 | 2024-12-31 | 3.8M | +183.5% |
| FY2023 | 2023-12-31 | 1.34M | +60.0% |
| FY2022 | 2022-12-31 | 836.83K | +7.4% |
| FY2021 | 2021-12-31 | 778.99K | — |
Selling, General & Admin vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +24.9% is the 2nd highest of 7, against a peer median of -3.6%.
- Over three fiscal years its annual growth of +91.9% compares with a peer median of +3.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $23.46M USD | -41.6% | -24.1% | — | |
| LTM Mar 2026 | CA$18.6M CAD | +58.0% | +35.4% | — | |
| LTM Mar 2026 | $18.36M USD | +21.1% | -6.5% | 244.9% | |
| FY2025 | $10.77M USD | +4.7% | +31.3% | — | |
| LTM Mar 2026 | $10.32M USD | -12.0% | -7.1% | — | |
EXOZeXoZymes, Inc. | LTM Mar 2026 | $5.71M USD | +24.9% | +91.9% | — |
| LTM Mar 2026 | $2.36M USD | -26.5% | +12.5% | — | |
| Peer median (excluding EXOZ) | — | -3.6% | +3.0% | 244.9% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 59.41K | 147.75K | 0 | 267.38K | 0 |
| Gross Profit | (59.41K) | (147.75K) | 0 | (267.38K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 454.45K | 348.08K | 527.48K | 1.87M | 3.71M |
| Selling, General & Admin | 778.99K | 836.83K | 1.34M | 3.8M | 5.91M |
| Operating Expenses | 1.23M | 1.18M | 1.8M | 5.66M | 9.72M |
| Depreciation & Amortization | 59.41K | 147.75K | 196.94K | 267.38K | 287.96K |
| EBITDA | (1.15M) | (1.18M) | (1.8M) | (5.59M) | (8.98M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (1.29M) | (1.33M) | (1.8M) | (5.93M) | (9.72M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 98 | 100 | 77.61K | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 83.74K | 98 | (199.9K) | 70.77K | 452.53K |
| Income Before Tax | (1.21M) | (1.33M) | (2M) | (5.86M) | (9.26M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 63.56K | 42.27K | 0 | (105.21K) |
| Net Income | (1.21M) | (1.4M) | (2.04M) | (5.86M) | (9.16M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| EPS (Diluted) | (0.15) | (0.17) | (0.25) | (0.72) | (1.09) |
| Weighted Avg Shares | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
| Weighted Avg Shares (Diluted) | 8.13M | 8.13M | 8.13M | 8.13M | 8.38M |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.